Secura Bio Announces the Presentation of New COPIKTRA® (duvelisib) Data for the Treatment of Patients with Relapsed or Refractory PTCL

SUMMERLIN, Nev., Dec. 14, 2021 /PRNewswire/ -- Secura Bio, Inc. (Secura Bio) - (www.securabio.com), an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies, today announced that new data for the treatment of relapsed or refractory(r/r) PTCL patients with COPIKTRA were presented at the 63^rd annual meeting of the American Society of Hematology (ASH) in Atlanta, Georgia.

Jonathan Brammer M.D. of The Ohio State University James Comprehensive Cancer Center presented the interim analysis of the phase 2 PRIMO trial of r/r PTCL patients treated with single-agent COPIKTRA 75mg BID for the first two months followed by 25mg BID until progression or unacceptable toxicity. 78 of a planned 125 patients were included in this analysis with a minimum follow-up of 6 months. The interim results include an ORR by IRC assessment of 50% (39/78 pts) and a CR of 32.1% (25/78) with a median duration of response of 233 days (range, 1-420+). Overall, the safety profile was consistent with previous studies. The trial is ongoing, with completion expected in 2022.

Other Duvelisib Presentations at the 2021 Annual ASH Meeting:

Press Release